About This Course

Inflammatory bowel disease (IBD) is a chronic relapsing condition affecting the gastrointestinal tract and presenting with digestive disorders and inflammation in the digestive system that can result from ulcerative colitis or Crohn’s disease.

Current treatments for IBD include biological medicines (biologics), which are agents derived from living systems. However, their high cost has formed a barrier to treatment access for many patients, generating the need for biosimilars. This course will provide an overview of the latest clinically relevant information on the use of biosimilars in IBD. 

This short course has been designed to teach healthcare providers everything they need to know about urogenital atrophy in order to increase recognition and improve patient care. It should take approximately 30 minutes to complete.

This course has a 2-year expiry date of 25th March 2026. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed.

CME/CPD Information

This course has been accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) with 1 European CME credit (ECMEC®).

A blue circle with yellow stars and a symbolDescription automatically generated

This accreditation certifies the quality and relevance of the educational content.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.

This course is also available on myCMEhttps://www.mycme.com/courses/fast-facts-biosimilars-in-inflammatory-bowel-disease-9379

Learning Outcomes

By the end of this course, you should be able to:

  • compare biosimilars to their reference biologics in terms of clinical equivalence

  • communicate and discuss biosimilar risks and benefits to patients with IBD

  • explain the concepts of extrapolation and nocebo effect when switching to a biosimilar.

  • identify patients who may or may not benefit from treatment with biosimilars.

Expert Faculty

This course has been made in close collaboration with:

Course curriculum

    1. Welcome to the Course

    1. Introduction to Precourse Quiz

    2. Precourse Quiz

    1. Biosimilars in IBD: What, Why, and How?

    1. Patient Communication and Education

    1. Clinical Scenarios

    1. Introduction to Final Quiz

    2. Final Quiz

    1. Conclusions and Take-Home Messages

    2. Course Feedback Survey

    3. Funding

About this course

  • Free
  • 11 lessons
  • 0 hours of video content